Global healthcare faces growing pressures. We explore how HEOR is evolving in 2025 to deliver value, meet payer needs, and support market access decisions.
Read More
Will Battershill and Hollie Wheat from Delta Hat discuss key insights into HTA decision-making from ISPOR Europe. Will explores the hot topic of incorporating patient and carer perspectives into decision-making, whilst Hollie dives into the use of surrogate endpoint evaluation in HTA decision-making.
In this four-part series, we will explore the various challenges facing orphan medicines entering the European market and suggest solutions that can help improve patient access. In the final part...
Read More
Challenges for orphan medicines entering the European market – Part 3: Economic evidence development
In this four-part series, we will explore the various challenges facing orphan medicines entering the European market and offer solutions that can help improve patient access. In Part 3 of...
Read More
Challenges for orphan medicines entering the European market – Part 2: Clinical evidence development
In this four-part series, we will explore the various challenges facing orphan medicines entering the European market and offer solutions that can help improve patient access. In Part 2 of...
Read More
In this four-part series, we will explore the various challenges facing orphan medicines entering the European market and offer solutions to help improve patient access. In Part 1, we will...
Read More
What is the EU Joint Clinical Assessment (JCA) and what does it mean for market access and reimbursment in Euorpe?
Discover how our symposium brought NHS and industry together to discuss the future of healthcare. We focused on innovation, collaboration, and transformation.
We’re delighted to announce that we will be exhibiting at ISPOR Europe in Barcelona over the 18th–20th November 2024. Mtech Access experts will be joined by our colleagues from across Petauri, including...
Read More
What clinical and economic evidence do US payers prefer to drive formulary decisions? How can you optimise your chances of preferential access in the US with the right evidence? How...
Read More
